Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors

Abstract

The invention relates to the novel products of formula (I): in which: Ra represents H, Hal, aryl or heteroaryl, which is optionally substituted; Rb represents H, Rc, —COORc-CO-Rc or —CO—NRcRd; where Rc represents alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, all optionally substituted; Rd represents H, alk or cycloalkyl; these products being in all the isomer forms and the salts, as medicaments, in particular as MET inhibitors.

1 ) A product of formula (I): 
       
         
           
           
               
               
           
         
         in which: 
         Ra represents a hydrogen atom; a halogen atom; an aryl radical; or a heteroaryl radical, these aryl and heteroaryl radicals being optionally substituted as indicated hereinafter; 
         Rb represents a hydrogen atom, an Rc, —COORc or —CO-Rc radical or a —CO—NRcRd radical; 
         where Rc represents an alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl radical, all these radicals being optionally substituted as indicated hereinafter; 
         Rd represents a hydrogen atom or an alkyl or cycloalkyl radical; 
         all the alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl radicals defined above being optionally substituted with one or more radicals chosen from halogen atoms, and hydroxyl, alkoxy, CN, CF 3 , —NR1R2, heterocycloalkyl, —COOH, —COOalk, —CONR1R2 and —NR1COR2 radicals; 
         the alkyl and cycloalkyl radicals also being optionally substituted with an aryl or heteroaryl radical, themselves optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, alkyl, alkoxy and NR3R4 radicals; 
         the cycloalkyl, heterocycloalkyl, aryl or heteroaryl radicals also being optionally substituted with an alkyl radical, itself optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, O-heterocycloalkyl, alkyl, alkoxy and NR3R4 radicals; 
         NR1R2 being such that: either, R1 and R2 being identical or different, one of R1 and R2 represents a hydrogen atom or an alkyl radical and the other of R1 and R2 represents a hydrogen atom, or a cycloalkyl radical or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from hydroxyl, alkoxy, NR3R4, heterocycloalkyl, heteroaryl or phenyl radicals, themselves optionally substituted; or R1 and R2 form, with the nitrogen atom to which they are attached, a cyclic radical containing from 3 to 10 ring members and optionally one or more other heteroatoms chosen from O, S, N and NH, this radical, including the possible NH that it contains, being optionally substituted; 
         NR3R4 being such that: either, R3 and R4 being identical or different, one of R3 and R4 represents a hydrogen atom or an alkyl radical and the other of R3 and R4 represents a hydrogen atom, or a cycloalkyl radical or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from hydroxyl, alkoxy, heterocycloalkyl, heteroaryl or phenyl radicals, themselves optionally substituted; or R3 and R4 form, with the nitrogen atom to which they are attached, a cyclic radical containing from 3 to 10 ring members and optionally one or more other heteroatoms chosen from O, S, N and NH, this radical, including the possible NH that it contains, being optionally substituted; 
         the cyclic radicals that R1 and R2 or R3 and R4, respectively, can form with the nitrogen atom to which they are attached, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms, hydroxyl, oxo, alkoxy, NH 2 , NHalk and N(alk) 2  radicals, and alkyl, phenyl, CH 2 -phenyl and heteroaryl radicals, such that, in the latter radicals, the alkyl, phenyl and heteroaryl radicals are themselves optionally substituted with one or more radicals chosen from halogen atoms and the following radicals: hydroxyl, alkyl and alkoxy containing from 1 to 4 carbon atoms, NH 2 , NHalk and N(alk) 2 ; 
         all the alkyl (alk) and alkoxy radicals above containing from 1 to 6 carbon atoms, racemic, enantiomeric and diastereoisomeric isomers, and pharmaceutically acceptable salts thereof. 
       
     
     
         2 ) The product of  claim 1 , in which:
 Ra represents a hydrogen atom; a halogen atom; or an aryl or heteroaryl radical, these aryl and heteroaryl radicals being optionally substituted as indicated hereinafter;   Rb represents a hydrogen atom, a —CO—Rc radical or a —CO—NRcRd radical;   where Rc represents an alkyl radical or a cycloalkyl radical, both optionally substituted with one or more radicals chosen from hydroxyl, alkoxy, NR1R2, heterocycloalkyl, aryl and heteroaryl radicals, themselves optionally substituted as indicated hereinafter;   Rd represents a hydrogen atom or an alkyl radical;   all the alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl radicals defined above being optionally substituted with one or more radicals chosen from halogen atoms, and hydroxyl, alkoxy, heterocycloalkyl, —NR1R2, —COOH, —COOalk and —CONR1R2 radicals;   the aryl or heteroaryl radicals also being optionally substituted with an alkyl radical, itself optionally substituted with one or more radicals chosen from halogen atoms and hydroxyl, O-heterocycloalkyl and alkoxy radicals;   NR1R2 being such that: either, R1 and R2 being identical or different, one of R1 and R2 represents a hydrogen atom or an alkyl radical and the other of R1 and R2 represents a hydrogen atom, or a cycloalkyl radical or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from hydroxyl, alkoxy, NR3R4, heterocycloalkyl, heteroaryl or phenyl radicals, themselves optionally substituted; or R1 and R2 form, with the nitrogen atom to which they are attached, a cyclic radical containing from 3 to 10 ring members and optionally one or more other heteroatoms chosen from O, S, N and NH, this radical, including the possible NH that it contains, being optionally substituted;   NR3R4 being such that: either, R3 and R4 being identical or different, one of R3 and R4 represents a hydrogen atom or an alkyl radical and the other of R3 and R4 represents a hydrogen atom, or a cycloalkyl radical or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from hydroxyl, alkoxy, heterocycloalkyl, heteroaryl or phenyl radicals, themselves optionally substituted; or R3 and R4 form, with the nitrogen atom to which they are attached, a cyclic radical containing from 3 to 10 ring members and optionally one or more other heteroatoms chosen from O, S, N and NH, this radical, including the possible NH that it contains, being optionally substituted;   the cyclic radicals that R1 and R2 or R3 and R4, respectively, can form, with the nitrogen atom to which they are attached, being optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms, hydroxyl and alkoxy radicals, and alkyl, phenyl and CH 2 -phenyl radicals, in which the alkyl or phenyl radicals are themselves optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and alkyl, hydroxyl, alkoxy, NH 2 , NHalk and N(alk) 2  radicals;   all the alkyl (alk) or alkoxy radicals above containing from 1 to 6 carbon atoms, racemic, enantiomeric and diastereoisomeric isomers, and pharmaceutically acceptable salts thereof.   
     
     
         3 ) The product according to  claim 1 , in which:
 Ra represents a hydrogen atom; a halogen atom; a phenyl radical optionally substituted as indicated hereinafter; or a pyrazolyl radical optionally substituted with a heterocycloalkyl radical or with an alkyl radical, itself optionally substituted with a hydroxyl radical or with an O-heterocycloalkylradical;   Rb represents a hydrogen atom, a —CO—Rc radical or a —CO—NRcRd radical;   where Rc represents an alkyl or cycloalkyl radical, both optionally substituted with one or more radicals chosen from the radicals hydroxyl, alkoxy, NR1R2 and phenyl, itself optionally substituted with one or more radicals chosen from halogen atoms, and hydroxyl, alkoxy, alkyl, NH 2 , NHalk and N(alk) 2  radicals;   Rd represents a hydrogen atom or an alkyl radical;   NR1R2 is such that: either, R1 and R2 being identical or different, one of R1 and R2 represents a hydrogen atom or an alkyl radical and the other of R1 and R2 represents a hydrogen atom, or a cycloalkyl radical or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from hydroxyl, alkoxy, NR3R4, or phenyl radicals, themselves optionally substituted; or R1 and R2 form, with the nitrogen atom to which they are attached, a cyclic radical containing from 4 to 7 ring members and optionally another heteroatom chosen from O, S, N and NH, this radical, including the possible NH that it contains, being optionally substituted;   NR3R4 being such that: either R3 and R4, which may be identical or different, represent a hydrogen atom or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from hydroxyl or alkoxy radicals; or R3 and R4 form, with the nitrogen atom to which they are attached, a cyclic radical containing from 4 to 7 ring members and optionally another heteroatom chosen from O, S, N and NH, this radical, including the possible NH that it contains, being optionally substituted;   the cyclic radicals that R1 and R2 or R3 and R4, respectively, can form, with the nitrogen atom to which they are attached, being optionally substituted with one or more radicals, which may be identical or different;   all the alkyl (alk) or alkoxy radicals above containing from 1 to 4 carbon atoms, racemic, enantiomeric and diastereoisomeric isomers, and pharmaceutically acceptable salts thereof.   
     
     
         4 ) The product according to  claim 1 , in which:
 Ra represents a hydrogen atom; a halogen atom; or a phenyl radical optionally substituted with one or more radicals chosen from halogen atoms and alkyl radicals; or a pyrazolyl radical optionally substituted with a piperidyl radical or with an alkyl radical, itself optionally substituted with a hydroxyl radical or with a tetrahydro-2H-pyran-2-yloxy radical;   Rb represents a hydrogen atom, a —CO-Rc radical or a —CO—NRcRd radical;   where Rc represents an alkyl or cycloalkyl radical optionally substituted with one or more radicals chosen from hydroxyl, alkoxy and NR1R2 radicals;   Rd represents a hydrogen atom;   NR1R2 being such that: either R1 and R2, which may be identical or different, represent a hydrogen atom or an alkyl radical optionally substituted with one or more radicals, which may be identical or different, chosen from hydroxyl, alkoxy, NH 2 , NHalk and N(alk) 2  radicals; or R1 and R2 form, with the nitrogen atom to which they are attached, a cyclic radical containing from 4 to 7 ring members and optionally another heteroatom chosen from O, S, N and NH, optionally substituted with an alkyl, phenyl or —CH 2 -phenyl radical, the latter radicals being themselves optionally substituted with one or more radicals, which may be identical or different, chosen from halogen atoms and alkyl, hydroxyl, alkoxy, NH 2 , NHalk and N(alk) 2  radicals;   all the alkyl (alk) or alkoxy radicals above containing from 1 to 4 carbon atoms,   racemic, enantiomeric and diastereoisomeric isomers, and pharmaceutically acceptable salts thereof.   
     
     
         5 ) The product according to  claim 1 , in which:
 Ra represents a hydrogen atom; an iodine atom; a phenyl radical optionally substituted with one or two radicals chosen from halogen atoms and a methyl radical; or a pyrazolyl radical optionally substituted with a piperidyl radical or with an ethyl radical, itself optionally substituted with a hydroxyl radical or with a tetrahydro-2H-pyran-2-yloxy radical;   Rb represents a hydrogen atom, a CO-Rc radical or a —CO—NRcRd radical;   where Rc represents a cyclopropyl radical or an alkyl radical optionally substituted with an alkoxy or NR1R2 radical;   Rd represents a hydrogen atom;   NR1R2 being such that: either R1 and R2, which may be identical or different, represent a hydrogen atom or an alkyl radical; or R1 and R2 form, with the nitrogen atom to which they are attached, a morpholinyl or piperazinyl radical optionally substituted on the second nitrogen atom with an alkyl radical;   the alkyl and alkoxy radicals above containing from 1 to 4 carbon atoms,   racemic, enantiomeric and diastereoisomeric isomers, and pharmaceutically acceptable salts thereof.   
     
     
         6 ) The product according to  claim 1 , corresponding to the following formulae:
 N-[6-([1,2,4]triazolo[4,3-a]pyridin-3-ylsulphanyl)-1,3-benzothiazol-2-yl]cyclopropanecarboxamide   1-[2-(morpholin-4-yl)ethyl]-3-[6-([1,2,4]triazolo[4,3-a]pyridin-3-ylsulphanyl)-1,3-benzothiazol-2-yl]urea   1-[2-(4-methylpiperazin-1-yl)ethyl]-3-[6-([1,2,4]triazolo[4,3-a]pyridin-3-ylsulphanyl)-1,3-benzothiazol-2-yl]urea   1-(2-methoxyethyl)-3-[6-([1,2,4]triazolo[4,3-a]pyridin-3-ylsulphanyl)-1,3-benzothiazol-2-yl]urea   6-[(6-iodo[1,2,4]triazolo[4,3-a]pyridin-3-yl)sulphanyl]-1,3-benzothiazol-2-amine   6-{[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulphanyl}-1,3-benzothiazol-2-amine   N-{6-[6-(4-fluorophenyl)[1,2,4]triazolo[4,3-a]pyridin-3-ylsulphanyl]-1,3-benzothiazol-2-yl}cyclopropanecarboxamide   6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulphanyl}-1,3-benzothiazol-2-amine   N-(6-{[6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulphanyl}-1,3-benzothiazol-2-yl)cyclopropanecarboxamide   N-(6-{[6-(1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulphanyl}-1,3-benzothiazol-2-yl)cyclopropanecarboxamide   N-(6-{[6-((3-fluoro-4-methyl)phenyl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulphanyl}-1,3-benzothiazol-2-yl)cyclopropanecarboxamide   N-(6-{[6-(3-fluorophenyl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulphanyl}-1,3-benzothiazol-2-yl)cyclopropanecarboxamide   N-(6-{[6-(1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulphanyl}-1,3-benzothiazol-2-yl)cyclopropanecarboxamide   N-(6-{[6-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]sulphanyl}-1,3-benzothiazol-2-yl)cyclopropanecarboxamide   N-(6-{[6-(1-piperidin-4-yl-1H-pyrazol-4-yl) [1,2,4]triazolo[4,3-a]pyridin-3-yl]sulphanyl}-1,3-benzothiazol-2-yl)cyclopropanecarboxamide   and pharmaceutically acceptable salts thereof.   
     
     
         7 ) A process for preparing the product according to  claim 1 , according to scheme 1 as defined hereinafter: 
       
         
           
           
               
               
           
         
       
       in which the substituents Ra and Rb have the meanings indicated in  claim 1 . 
     
     
         8 ) A process for preparing the product according to  claim 1 , according to scheme 2 as defined hereinafter: 
       
         
           
           
               
               
           
         
       
       in which the substituents Ra and Rb have the meanings indicated in  claim 1 . 
     
     
         9 ) A process for preparing the product according to  claim 1 , according to scheme 3 as defined hereinafter: 
       
         
           
           
               
               
           
         
         in which the substituents Ra and Rc have the meanings indicated in  claim 1 . 
       
     
     
         10 ) A pharmaceutical composition comprising the product of  claim 1 , and pharmaceutically acceptable salts thereof. 
     
     
         11 ) A pharmaceutical composition comprising the product of  claim 6 , and pharmaceutically acceptable salts thereof. 
     
     
         12 ) A pharmaceutical composition containing, as active ingredient, at least one product according to  claim 1 , or a pharmaceutically acceptable salt of said product or a prodrug of said product, and a pharmaceutically acceptable carrier. 
     
     
         13 ) A method of inhibiting the activity of the MET protein kinase and mutant forms thereof in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the product according to  claim 1 , or pharmaceutically acceptable salts thereof. 
     
     
         14 ) The method of  claim 13 , wherein said protein kinase is in a cell culture. 
     
     
         15 ) A method of treating or preventing a disease in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the product according to  claim 1 , wherein said disease is chosen from the following groups: blood vessel proliferation disorders, fibrotic disorders, “mesangial” cell proliferation disorders, metabolic disorders, allergies, asthma, thrombosis, nervous system diseases, retinopathy, psoriasis, rheumatoic arthritis, diabetes, muscle degeneration and cancers. 
     
     
         16 ) A method of treating cancers in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the product according to  claim 1 . 
     
     
         17 ) The method according to  claim 16 , wherein solid or liquid tumours are treated. 
     
     
         18 ) The method according to  claim 16 , for wherein said cancers are resistant to cytotoxic agents. 
     
     
         19 ) The method according to  claim 16 , wherein primary tumours and/or metastases are treated, in particular in gastric, hepatic, renal, ovarian, colon, prostate and lung (NSCLC and SCLC) cancers, glioblastomas, thyroid, bladder or breast cancers, in melanoma, in lymphoid or myeloid hematopoietic tumours, in sarcomas, in brain, larynx or lympathic system tumours, bone cancers and pancreatic cancers. 
     
     
         20 ) (canceled) 
     
     
         21 ) (canceled) 
     
     
         22 ) The product according to  claim 1 , wherein said product is a kinase inhibitor. 
     
     
         23 ) The product according to  claim 1 , wherein said product is a MET inhibitor. 
     
     
         24 ) A product having one of the following formulas: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         in which Ra, Rb and Rc have the definitions indicated in  claim 1 , and R represents a t-butyl or phenyl radical.